Key facts
- This page summarizes Roger Pomerantz's Form 4 filing for Viracta Therapeutics, Inc. (VIRX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Jun 2024, 19:40.
Roger Pomerantz - 20 Jun 2024 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)
- Reporting relationship
- Director
- Issuer ticker
- VIRX
- Reported as of
- 20 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jun 2024, 19:40:56 UTC
- Prior SEC filing
- 07 Jun 2024
- Next SEC filing
- 12 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael E. Faerm, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Roger Pomerantz filed Form 4 for Viracta Therapeutics, Inc. (VIRX) on 24 Jun 2024.
Change
- Previous filing in this sequence was filed on 07 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VIRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 20 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $0.5690
- Footnotes
- F1
VIRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +18,750
- Change %
- Price
- $0.000000
- Shares after
- 18,750
- Date
- 20 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,750
- Exercise price
- $0.5690
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.